Open AccessRosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts
Author(s) -
Shiwen Xu,
Mark Eastwood,
Richard Stratton,
Christopher P. Denton,
Andrew Leask,
David Abraham
Publication year - 2009
Publication title -
rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.957
H-Index - 173
eISSN - 1462-0332
pISSN - 1462-0324
DOI - 10.1093/rheumatology/kep371
Subject(s) - rosiglitazone , peroxisome proliferator activated receptor , medicine , agonist , western blot , fibrosis , phenotype , ppar agonist , scleroderma (fungus) , endocrinology , receptor , fibroblast , pathology , biology , cell culture , gene , biochemistry , genetics , inoculation
The transcription factor peroxisome proliferator-activated receptor (PPAR)-gamma plays an important role in controlling cell differentiation. The aim of the present study was to examine whether PPAR-gamma expression was reduced in skin scleroderma fibroblasts and whether PPAR-gamma agonists could suppress the persistent fibrotic phenotype of skin scleroderma fibroblasts.